2017
DOI: 10.1007/s00134-017-4990-y
|View full text |Cite
|
Sign up to set email alerts
|

Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…The recognition of C. glabrata candidemia is frequently delayed, resulting in dramatic clinical deterioration and death of critically ill ICU patients [37], which might explain the higher 7-day mortality rate of C. glabrata ICUAC. Therefore, these results highlight the importance of the exploration studies of early risk management of ICUAC, such as prophylactic antifungal therapy, biomarker-based preemptive therapy and risk-based empirical therapy in patients with ICUAC, especially C. glabrata ICUAC [38,39].…”
Section: Discussionmentioning
confidence: 86%
“…The recognition of C. glabrata candidemia is frequently delayed, resulting in dramatic clinical deterioration and death of critically ill ICU patients [37], which might explain the higher 7-day mortality rate of C. glabrata ICUAC. Therefore, these results highlight the importance of the exploration studies of early risk management of ICUAC, such as prophylactic antifungal therapy, biomarker-based preemptive therapy and risk-based empirical therapy in patients with ICUAC, especially C. glabrata ICUAC [38,39].…”
Section: Discussionmentioning
confidence: 86%
“…Early diagnosis of systemic candidiasis with the aid of novel, sensitive biomarkers helps other members of the team to properly design the following procedures of ASFP targeted toward the optimization of antifungal use and prevention of antifungal resistance emergence without the loss of the desired clinical outcome [7, 62, 63]. Use of a preauthorization-based ASFP strategy (i.e., front-end strategy) facilitates the CMLS to direct the whole ASFP team towards a successful clinical outcome and an optimized antifungal therapy by the proper selection of a biomarker with a high sensitivity and specificity [62].…”
Section: Antifungal Stewardship Policy Structurementioning
confidence: 99%
“…The biomarker-guided preemptive therapy of IFI (e.g., IC) seems to be a promising approach having such benefits as the optimized use of antifungals, lower chance of antifungal resistance development, lower healthcare costs, shorter length of hospital stay, and higher survival rate [63].…”
Section: Antifungal Stewardship Policy Structurementioning
confidence: 99%
“…Furthermore, biomarkers could not accurately predict candidemia in many conditions. BGD performed high percentage of false-positive results due to transfusion of human blood products, hemodialysis, infection by some Gram-positive bacteria, use of certain beta-lactam antibiotics, cellulose dressings or enteral nutrition, and disruptions of gastrointestinal (GI) tract integrity [13,14].Therefore, the demand for the development of more rapid and accurate approaches to differentiate candidemia from bacterial infections is not only evident but also urgent, such approaches could aid ICU physicians in making informed decision regarding the initiation of antifungal therapy [15,16].…”
Section: Introductionmentioning
confidence: 99%